Initiatives

The SHIONOGI Group selects suppliers based on the Procurement Policy with due consideration given to geopolitical risks and risks specific to the industries and raw materials that we deal with.
Our domestic group has more than 4,000 suppliers around the world. We designate “suppliers necessary for us to provide the market with our products and services on a stable basis” as significant suppliers and identify such suppliers according to the following steps.

The SHIONOGI Group is striving to realize sustainable procurement by establishing a PDCA cycle based on, for example, the formulation of the Business Partner Code of Conduct, the assessment of risks and identification of problems through surveys and audits on ESG elements, and the development of improvement plans through communication with suppliers.

＊1 Platform in which scorecards are used to assess a broad range of non-financial management systems including supplier environment, labor & human rights, ethics and sustainable procurement impacts

At SHIONOGI’s manufacturing and research sites, we conduct environmental impact assessment regarding all aspects of their operations from the purchase of raw materials to disposal. Our awareness raising targets not only high-risk in-house operations but also outsourced services, waste disposal operators and other related parties. An emergency communication system is also established between SHIONOGI and its suppliers.

Our Business Partner ESG Management Guidance sets out EHS risk categories and risk management procedures for suppliers and stipulates which conditions they must meet according to their assigned management level. For important investigational new drugs and pharmaceutical raw material suppliers, we carry out surveys using the PSCI’s self-assessment questionnaire (SAQ)—to confirm the supplier’s status in areas including ethics, human rights and labor, environment, health and safety, and their management systems—in conjunction with on-site audits.

Our on-site audits include confirmation of the risks of the relevant suppliers through, for example, assessment of the safety of manufacturing processes and assessment of compliance with the laws and regulations that need to be observed at the operating sites.

For significant suppliers, we use EcoVadis, a rating platform for fair and objective assessment of corporate social responsibility and sustainable procurement, and assess suppliers in order of priority.

＊2 PV: Process validation; confirmation and documentation that the process is valid for permanently manufacturing products of the target quality when operated under a permissible range of conditions set based on the results of industrialization research, the past manufacturing records of similar products, or other such data and in consideration of variables likely to affect the preset product quality (physical properties of raw and other materials, operating conditions, etc.)

＊3 GMP: Good Manufacturing Practice: international standards for the manufacturing and quality control of pharmaceutical products; the GMP-conforming manufacturing of pharmaceutical products is required to follow GMP procedures and guidelines concerning operations such as the delivery of raw materials, inspection, manufacturing, packaging, shipment management, storage, and collection and disposal.

＊4  Important items: antimicrobial resistance (AMR)-related items and business continuity plan (BCP)-related items

The SHIONOGI Group aims to contribute to realizing a sustainable and sound society through business activities in cooperation with suppliers.

For such cooperation, we conduct assessment and selection in accordance with the Procurement Policy. In addition, in order to ensure our commitment in cooperation with suppliers, we exchange necessary documents, such as contracts stipulating their endorsement of our Business Partner Code of Conduct, before proceeding with the transaction. We are working toward receiving the endorsement of all our suppliers.

In addition, the SHIONOGI Group is making efforts to enhance supplier engagement. We are asking significant suppliers to conduct a risk assessment using the EcoVadis platform and implement corrective actions, while offering explanatory sessions and  to provide support for addressing ESG challenges. For details on specific initiatives, please see below.

For supplier risk management and cooperation with suppliers, the targets and results for each fiscal year are shown below.

We will continue to work steadily with the cooperation of the entire SHIONOGI Group toward the targets set in light of the entire supply chain, while disclosing our progress.

For the rationale for setting human rights and climate change targets, please see below.

At SHIONOGI, we are striving to realize sustainable procurement by ensuring that SOPs include the items related to social issues that employees engaged in procurement operations need to understand and follow, such as human rights, labor, and the environment, and by providing a training program so that the employees are fully familiarized with such items. In FY2022, 74 employees engaged in procurement operations took the SOP training program.

In FY2021, we provided all the domestic group’s employees, including those engaged in procurement operations, with E-learning training on the Procurement Policy and the Business Partner Code of Conduct. (Participation rate: 84%)

In January 2023, we launched a joint delivery in compliance with the Good Distribution Practice (GDP) for pharmaceutical products for the first time in the pharmaceutical industry in cooperation with Ono Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, and S.D.Collabo Co., Ltd. Through this joint delivery, we are aiming to achieve the following effects: